Cryptic exons as a source of increased diversity of Ewing tumor-associated EWS-FLI1 chimeric products

被引:10
作者
Kovar, H
Jugovic, D
Melot, T
Zoubek, A
Lenoir, G
Fink, FM
Philip, I
Turc-Carel, C
Thomas, G
Zucman-Rossi, J
机构
[1] St Anna Kinderspital, Childrens Canc Res Inst, A-1090 Vienna, Austria
[2] Inst Curie, INSERM U509, Paris, France
[3] Int Agcy Res Canc, F-69372 Lyon, France
[4] Univ Innsbruck Hosp, Dept Pediat, A-6020 Innsbruck, Austria
[5] Ctr Leon Berard, F-69373 Lyon, France
[6] Fac Med Nice, CNRS UNA UMR 6549, Nice, France
[7] Fdn Jean Dausset, CEPH, INSERM U434, Paris, France
关键词
D O I
10.1006/geno.1999.5919
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the Ewing family of tumors (EFT), the EWS gene is rearranged with members of the ets oncogene family. Variability in genomic breakpoint locations is the source of significant heterogeneity in fusion product structure. As a consequence of variably included exon sequences from the two partner genes, a variable amount of additional peptide sequence is inserted in between the minimal transforming domains. Some of this molecular diversity has recently been correlated with disparate clinical outcome. Here we report on cryptic exons found in the chimeric RNA of three EFT with different EWS-FLI1 fusions, In two tumors, the emergence of a cryptic exon from FLI1 intron 5 in the chimeric RNA was apparently unrelated to the genomic rearrangement that occurred in FLI1 introns 4 and 5, respectively, In one case, a novel exon was generated through the creation of an artificial splice acceptor site in FLI1 intron 6 by the genomic rearrangement that occurred in EWS intron 8. These results further extend the spectrum of molecular diversity in EFT. (C) 1999 Academic Press.
引用
收藏
页码:371 / 374
页数:4
相关论文
共 13 条
[1]   DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION PROPERTIES OF THE EWS-FLI-1 FUSION PROTEIN RESULTING FROM THE T(1122) TRANSLOCATION IN EWING SARCOMA [J].
BAILLY, RA ;
BOSSELUT, R ;
ZUCMAN, J ;
CORMIER, F ;
DELATTRE, O ;
ROUSSEL, M ;
THOMAS, G ;
GHYSDAEL, J .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (05) :3230-3241
[2]   Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains [J].
Carrère, S ;
Verger, A ;
Flourens, A ;
Stehelin, D ;
Duterque-Coquillaud, M .
ONCOGENE, 1998, 16 (25) :3261-3268
[3]   EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma [J].
de Alava, E ;
Kawai, A ;
Healey, JH ;
Fligman, I ;
Meyers, PA ;
Huvos, AG ;
Gerald, WL ;
Jhanwar, SC ;
Argani, P ;
Antonescu, CR ;
Pardo-Mindan, FJ ;
Ginsberg, J ;
Womer, R ;
Lawlor, ER ;
Wunder, J ;
Andrulis, I ;
Sorensen, PHB ;
Barr, FG ;
Ladanyi, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1248-1255
[4]   THE EWING FAMILY OF TUMORS - A SUBGROUP OF SMALL-ROUND-CELL TUMORS DEFINED BY SPECIFIC CHIMERIC TRANSCRIPTS [J].
DELATTRE, O ;
ZUCMAN, J ;
MELOT, T ;
GARAU, XS ;
ZUCKER, JM ;
LENOIR, GM ;
AMBROS, PF ;
SHEER, D ;
TURCCAREL, C ;
TRICHE, TJ ;
AURIAS, A ;
THOMAS, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (05) :294-299
[5]  
DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865
[6]  
Kovar H, 1998, Sarcoma, V2, P3, DOI 10.1080/13577149878109
[7]  
Lin PP, 1999, CANCER RES, V59, P1428
[8]   EWING SARCOMA 11-22 TRANSLOCATION PRODUCES A CHIMERIC TRANSCRIPTION FACTOR THAT REQUIRES THE DNA-BINDING DOMAIN ENCODED BY FLI1 FOR TRANSFORMATION [J].
MAY, WA ;
GISHIZKY, ML ;
LESSNICK, SL ;
LUNSFORD, LB ;
LEWIS, BC ;
DELATTRE, O ;
ZUCMAN, J ;
THOMAS, G ;
DENNY, CT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5752-5756
[9]  
OHNO T, 1993, CANCER RES, V53, P5859
[10]   Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? [J].
Zoubek, A ;
DockhornDworniczak, B ;
Delattre, O ;
Christiansen, H ;
Niggli, F ;
GattererMenz, I ;
Smith, TL ;
Jurgens, H ;
Gadner, H ;
Kovar, H .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1245-1251